A practical reference on prothymosin alpha: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-05. Anything still debated is marked as such rather than presented as settled.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
| Property | Value | Notes |
|---|---|---|
| Detection wavelength | 214 nm | Peptide bond absorption; 280 nm is not useful. |
| Confirmatory method | Electrospray mass spectrometry | Verifies mass near 3108 Da. |
| Solution stability | Limited at room temperature | Aqueous solutions degrade faster than powder. |
| Recommended storage | -20 °C | For lyophilized powder; protect from moisture. |
| Purity criterion | ≥95% by RP-HPLC | Typical research-grade specification. |
Lyophilized thymosin alpha 1 is typically stored refrigerated at 2 to 8 degrees Celsius and kept away from light. Reconstituted solutions are less stable and are usually used promptly after preparation. Repeated freeze-thaw cycles are avoided because they can promote aggregation and loss of activity. The peptide adsorbs to some plastic and glass surfaces, so a carrier protein is often added to dilute working solutions. Manufacturer instructions and published protocols both govern handling.
Identity and purity testing for thymosin alpha 1 relies mainly on reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatography separates the parent peptide from truncated or modified variants, while mass spectrometry confirms the expected molecular mass. Amino acid analysis and peptide mapping provide additional sequence confirmation. Counterion content, water content, and residual solvents are measured separately as part of specification testing. No single method captures every attribute, so laboratories combine several techniques.
The peptide lacks cysteine, methionine, and tryptophan, so disulfide scrambling and sulfur oxidation are not major degradation routes. Instead, aspartate residues can undergo isomerization or cyclization to succinimide intermediates, generating isoaspartate variants. Hydrolysis of peptide bonds also occurs slowly in solution. These changes may reduce biological activity even when the main peak remains detectable. Stability studies therefore track both potency and the appearance of related substances.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
Blood dyscrasias (e.g., agranulocytosis, leukopenia, and neutropaenia), which is more common in patients on clozapine. Metabolic syndrome and other metabolic problems such as type II diabetes mellitus — particularly common with clozapine, olanzapine and zotepine. In American studies African Americans appeared to be at a heightened risk for developing type II diabetes mellitus. Evidence suggests that females are more sensitive to the metabolic side effects of first-generation antipsychotic drugs than males. Metabolic adverse effects appear to be mediated by antagonizing the dopamine D2, the histamine H1 and serotonin 5-HT2C receptors and perhaps by interacting with other neurochemical pathways in the central nervous system. Neuroleptic malignant syndrome, a potentially fatal condition characterized by: Autonomic instability, which can manifest with tachycardia, nausea, vomiting, diaphoresis, etc. Hyperthermia — elevated body temperature. Mental status change (confusion, hallucinations, coma, etc.) Muscle rigidity Laboratory abnormalities (e.g., elevated creatine kinase, reduced iron plasma levels, electrolyte abnormalities, etc.) Pancreatitis QT interval prolongation — more prominent in those treated with amisulpride, pimozide, sertindole, thioridazine and ziprasidone. Torsades de pointes Seizures, particularly in people treated with chlorpromazine and clozapine. Thromboembolism Myocardial infarction Stroke Pisa syndrome Some atypical antipsychotics are associated with considerable weight gain, diabetes, and the risk of metabolic syndrome.
In the context of the fall of communism throughout Eastern Europe during the revolutions of 1989, a protest in support of Reformed pastor László Tőkés that began in December 1989 in Timișoara quickly escalated into a national uprising against the communist regime, ultimately resulting in the execution of Ceaușescu and his wife Elena on 25 December 1989. An interim council composed of figures from civil society and former communist officials assumed control of the government, and Ion Iliescu became the provisional president of the country. The new government reversed many of the authoritarian communist policies and dismissed several leaders of the former regime, although still influenced by members of the former regime (the basis for the Golaniad, and Mineriads). In May 1990, the first free elections in Romania since the 1937 elections were held, with Iliescu of the National Salvation Front winning the presidency with 85% of the vote. In 1992, he was reelected in the first election after the adoption of a permanent constitution via a referendum held the previous year. Illiescu lost the 1996 election to Emil Constantinescu, but returned to power in 2000. Traian Băsescu was elected president in 2004 and 2009, serving until 2014 at which point Klaus Iohannis succeeded him, being re-elected in 2019 and serving until 2025. During these years several events occurred. In 2009, the country was bailed out by the International Monetary Fund as result of the Great Recession in Europe following the 2008 financial crisis.
=== Workplace accidents === Women are underrepresented in sectors associated with higher physical risks, which contributes to lower reported rates of workplace accidents. Fewer than 26% of non-fatal work accidents involve women. Similarly, women account for 25% of workplace accidents resulting in permanent disability. Fatal work accidents are substantially more common among men, with 25 times more men than women dying on the job.
Soft balancing was developed in the 2000s to account for the contemporary anomaly of the unipolar unbalanced world. Thomas Mowle and David Sacko describe "soft balancing" as "balancing that does not balance at all." These theoretical efforts are counter-productive, since Realism and unipolarity are compatible and structural realism should rather develop a set of hypotheses for a unipolar world: "Scholars do not need to desperately search for signs of balancing, they do not need to soften balancing beyond recognition, and they do not need to stand to watch for the first glimmering of a new multipolar dawn." Campbell Craig explained the development of soft balancing theory on the Thomas Kuhn's three-stage model how scholarly communities respond to anomalies that seem clearly to defy their core theoretical predictions:
Sources: en.wikipedia.org
NpOF3 and NpOF4 can be produced by reacting neptunium oxides with anhydrous hydrogen fluoride at various temperatures. Neptunium also forms a wide variety of fluoride compounds with various elements. Some of these that have been characterized include CsNpF6, Rb2NpF7, Na3NpF8, and K3NpO2F5. Two neptunium chlorides, NpCl3 and NpCl4, have been characterized. Although several attempts to obtain NpCl5 have been made, they have not been successful. NpCl3 is produced by reducing neptunium dioxide with hydrogen and carbon tetrachloride (CCl4) and NpCl4 by reacting a neptunium oxide with CCl4 at around 500 °C. Other neptunium chloride compounds have also been reported, including NpOCl2, Cs2NpCl6, Cs3NpO2Cl4, and Cs2NaNpCl6. Neptunium bromides NpBr3 and NpBr4 have also been produced; the latter by reacting aluminium bromide with NpO2 at 350 °C and the former in an almost identical procedure but with zinc present. The neptunium iodide NpI3 has also been prepared by the same method as NpBr3.
In November 2013, the FDA announced it would remove the usage restrictions for rosiglitazone in patients with coronary artery disease. The new recommendations were largely based on the reasoning that prior meta-analyses leading to the original restrictions were not designed to assess cardiac outcomes and, thus, not uniformly collected or adjudicated. In contrast, one of the largest trials (RECORD trial) that was specifically designed to assess cardiac outcomes found no increased risk of myocardial infarction with rosiglitazone use, even after independent re-evaluation for FDA review. A 2013 meta-analysis concluded that use of pioglitazone is associated with a slightly higher risk of bladder cancer compared to the general population. The authors of the same analysis recommended that other blood sugar lowering agents be considered in people with other risk factors for bladder cancer such as cigarette smoking, family history, or exposure to certain forms of chemotherapy. A 2020 Cochrane systematic review did not find enough evidence of reduction of all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke or end-stage renal disease when comparing metformin monotherapy to Thiazolidinedione for treatment of type 2 diabetes. Thiazolidinediones reduce bone mineral density and increase the risk of fractures in women, possibly as a result of biasing the differentiation of bone marrow stromal cells away from osteoblast differentiation and toward adipocyte formation.
==== 2009 ==== A top-level Georgian official suspected in February 2009 that there was a connection between one German expert working for Tagliavini and Russian Gazprom-affiliated companies. In October 2009, an anonymous source told the news agency that Gazprom paid German expert. The news agency alleged that German Foreign Minister Frank-Walter Steinmeier was promised a job at Gazprom for his influence on the report. Germany was the largest trade partner of Russia as of August 2008. In September 2009, before the report was published, former Prime Minister of Estonia Mart Laar said in an interview that the commission forgot "that during the war, no Georgian soldier, no plane, no other military equipment left the legal, internationally recognized territory of Georgia. It was Georgian territory, and no Georgian soldier [left] the borders of Georgia." After the publication of the report, Laar stated that the report stated that Russian accusation of genocide was false. However, the commission did not declare Russia as aggressor, because Europe would have to hold tribunal on the Russian war crimes. Before the report was published, Russian Foreign Ministry spokesman Igor Lyakin-Frolov said Russian authorities had been "absolutely fair and honest" during investigation. He did not doubt neutrality of the report and hoped that the blame would be pinned on Ukraine for arming Georgia; however, he also stated it would be "unfair" if both Russia and Georgia were found guilty. After the report was published, Russian and South Ossetian officials mostly approved of the report.
Sources: en.wikipedia.org
Reverse-phase HPLC with ultraviolet detection at 214 nm is common. Mass spectrometry is used to confirm molecular identity and detect modifications. Immunoassays exist but may not distinguish the intact peptide from fragments.
The lyophilized powder is usually stored at -20 °C or below. Dissolved solutions are less stable and should be prepared fresh when possible. Freeze-thaw cycling can reduce integrity.
It lacks aromatic residues, so it does not absorb strongly at 280 nm. Its negative charge and hydrophilic nature can affect chromatographic retention. These properties require method development for reliable separation.
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.